Beijing Xuanwu Hospital: Alzheimer's disease has a marker?

Alzheimer's disease (AD), as a clinically heterogeneous and complex neurodegenerative disease, is considered to be the most common type of dementia, which brings a heavy burden to patients and families
.

The onset of AD is a continuous gradual process, from asymptomatic state to mild cognitive impairment, to clinical diagnosis of dementia

The onset of AD is a continuous gradual process, from asymptomatic state to mild cognitive impairment, to clinical diagnosis of dementia

prevention

As the main immune cells in the brain , microglia have been shown to be important regulators of AD
.

A large number of studies have explored the value of cerebrospinal fluid (CSF) sTREM2 level as a biomarker for the diagnosis and prediction of AD

immunity

In order to comprehensively evaluate the relationship between CSF sTREM2 levels and AD risk, a professor from Xuanwu Hospital of Capital Medical University in China conducted a meta-analysis and the results were published in Frontiers in Aging Neuroscience
.

Researchers conducted a systematic literature search using MEDLINE, EMBASE and Web of Science databases

The overall results show that higher CSF sTREM2 levels are associated with AD risk [standardized mean difference (SMD)=0.
428, 95%CI (0.
213, 0.
643), I2=81.
1%]
.

However, the analysis of the "age difference ≤ 2 years" subgroup showed that sTREM2 was not associated with AD [SMD=0.

Higher CSF sTREM2 levels are associated with AD risk [standardized mean difference (SMD)=0.

The difference in CSF sTREM2 between group D and control group was positively correlated with the difference in age

In a study where the AD group and the control group were about the same age, the sensitivity analysis results of CSF sTREM2 level and AD risk
.

Through further subgroup analysis of 5 age-matched studies (495 cases and 364 cases of control) according to the measurement method and the inclusion criteria required for pathological evidence of AD, there is no corresponding set of SMD and the significance of the results.
Changes are observed
.

In the sensitivity analysis, the meta-analysis results of the "age difference ≤ 2 years" group are robust

In summary, the existing high-quality evidence does not support the association between CSF sTREM2 levels and AD risk
.

The age match between AD patients and the cognitive accessibility control group is the main factor affecting the results

In summary, the existing high-quality evidence does not support the association between CSF sTREM2 levels and AD risk

references:

Age Matching Is Essential for the Study of Cerebrospinal Fluid sTREM2 Levels and Alzheimer's Disease Risk: A Meta-Analysis.
https://doi.
org/10.
3389/fnagi.
2021.
775432

Age Matching Is Essential for the Study of Cerebrospinal Fluid sTREM2 Levels and Alzheimer's Disease Risk: A Meta-Analysis.
Leave a message here